Clinical Trial

A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

Name: A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies — clinical trial record (NCT07628582)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label and dose-escalation clinical study to evaluate the LVIVO-TaVec122 product in adult subjects with Relapsed/Refractory B-cell Malignancies.

Trial Details

NCT Number	NCT07628582
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Nanjing Legend Biotech Co.
Conditions	Relapsed/Refractory B-cell Malignancies
Enrollment	48 participants
Start Date	2026-09-15
Primary Completion	2028-10-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-05